PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE INPATIENTS WITH A FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME

被引：0
|
作者：
Aoki, Tomokazu [1 ]
Ueba, Tetsuya [2 ]
Miyatake, Shin-Ichi [3 ]
Nozaki, Kazuhiko [4 ]
Arakawa, Yoshiki [5 ]
Miyamoto, Susumu [5 ]
Tsukahara, Tetsuya [1 ]
Matsutani, Masao [6 ]
机构：
[1] Kyoto Med Ctr, Kyoto, Japan
[2] Kochi Univ, Kochi 780, Japan
[3] Osaka Med Coll, Osaka, Japan
[4] Shiga Univ, Otsu, Shiga, Japan
[5] Kyoto Univ, Kyoto, Japan
[6] Saitama Med Univ, Saitama, Japan
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou237.5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AT-05
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence.
    Ahluwalia, Manmeet Singh
    Peereboom, David M.
    Ciolfi, Marci
    Schilero, Cathy
    Hobbs, Brian
    Ciesielski, Michael J.
    Fenstermaker, Robert Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
    Yung, WKA
    Albright, RE
    Olson, J
    Fredericks, R
    Fink, K
    Prados, MD
    Brada, M
    Spence, A
    Hohl, RJ
    Shapiro, W
    Glantz, M
    Greenberg, H
    Selker, RG
    Vick, NA
    Rampling, R
    Friedman, H
    Phillips, P
    Bruner, J
    Yue, N
    Osoba, D
    Zaknoen, S
    Levin, VA
    BRITISH JOURNAL OF CANCER, 2000, 83 (05) : 588 - 593
  • [33] A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
    W K A Yung
    R E Albright
    J Olson
    R Fredericks
    K Fink
    M D Prados
    M Brada
    A Spence
    R J Hohl
    W Shapiro
    M Glantz
    H Greenberg
    R G Selker
    N A Vick
    R Rampling
    H Friedman
    P Phillips
    J Bruner
    N Yue
    D Osoba
    S Zaknoen
    V A Levin
    British Journal of Cancer, 2000, 83 : 588 - 593
  • [34] Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: A dose-escalation study
    Chang, AY
    Boros, L
    Garrow, GC
    Asbury, RF
    Hui, LF
    SEMINARS IN ONCOLOGY, 1996, 23 (03) : 74 - 77
  • [35] Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
    Gavin M. Marx
    Nicholas Pavlakis
    Sally McCowatt
    Frances M. Boyle
    John A. Levi
    David R. Bell
    Raymond Cook
    Michael Biggs
    Nicholas Little
    Helen R. Wheeler
    Journal of Neuro-Oncology, 2001, 54 : 31 - 38
  • [36] A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme
    Camilo E. Fadul
    Linda S. Kingman
    Louise P. Meyer
    Bernard F. Cole
    Clifford J. Eskey
    C. Harker Rhodes
    David W. Roberts
    Herbert B. Newton
    J. Marc Pipas
    Journal of Neuro-Oncology, 2008, 90
  • [37] Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
    Marx, GM
    Pavlakis, N
    McCowatt, S
    Boyle, FM
    Levi, JA
    Bell, DR
    Cook, R
    Biggs, M
    Little, N
    Wheeler, HR
    JOURNAL OF NEURO-ONCOLOGY, 2001, 54 (01) : 31 - 38
  • [38] A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme
    Fadul, Camilo E.
    Kingman, Linda S.
    Meyer, Louise P.
    Cole, Bernard F.
    Eskey, Clifford J.
    Rhodes, C. Harker
    Roberts, David W.
    Newton, Herbert B.
    Pipas, J. Marc
    JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (02) : 229 - 235
  • [39] Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC)
    Preti, P
    Poggi, G
    Cuomo, AM
    Della Cuna, FSR
    Zambelli, A
    Pavesi, L
    JOURNAL OF CHEMOTHERAPY, 1998, 10 (06) : 492 - 495
  • [40] IFOSFAMIDE CARBOPLATIN ETOPOSIDE (ICE) FOR RECURRENT MALIGNANT SOLID TUMORS OF CHILDHOOD - A PEDIATRIC-ONCOLOGY-GROUP PHASE I/II STUDY
    KUNG, FH
    DESAI, SJ
    DICKERMAN, JD
    GOORIN, AM
    HARRIS, MB
    INOUE, S
    KRISCHER, JP
    MURPHY, SB
    PRATT, CB
    TOLEDANO, S
    WILEY, JM
    YU, AL
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1995, 17 (03) : 265 - 269
12345